‘Plus’ Tagged Posts

Nursing 361: SALUD and Medline Plus

...

 

The right way to Pronounce Fosamax Plus D

 

Adcetris Plus Chemotherapy Accepted for Peripheral T-Cell Lymphoma

 

Если Вы считаете, что включение ip-адреса нужного Вам интернет-ресурса в “Единый реестр…” или “Реестр доменных имен…” произошло по ошибке, или оно нарушает Ваши законные права, пожалуйста, обращайтесь непосредственно к уполномоченному органу по координатам на интернет-сайте реестра.

Перейти на сайт
Универсального сервиса проверки ограничения доступа к сайтам или страницам сайтов сети “Интернет”

Section III CLL14 examine evaluating Venclexta plus Gazyva to deal with CLL meets its major endpoint

 

Genentech, a member of the Roche Group , introduced as we speak that the randomized Section III CLL14 examine, which evaluated fixed-duration Venclexta® (venetoclax) together with Gazyva® (obinutuzumab) in folks with beforehand untreated power lymphocytic leukemia (CLL) and co-existing medical circumstances, met its major endpoint and confirmed a statistically vital discount within the danger of illness worsening or dying (progression-free survival [PFS] as assessed by investigator) in comparison with standard-of-care Gazyva plus chlorambucil. The outcomes confirmed that no new security alerts or enhance in identified toxicities of Venclexta or Gazyva have been noticed with the remedy mixture.

“Individuals with power lymphocytic leukemia proceed to want extra remedy choices as a result of some sufferers are unable to tolerate chemotherapy regimens as a result of their underlying well being,” mentioned Sandra Horning, M.D., chief medical officer and head of International Product Growth. “CLL14 is the primary examine to point out superior progression-free survival for Venclexta plus Gazyva in comparison with a standard-of-care routine. We are going to work with well being authorities to deliver this potential chemotherapy-free remedy choice to individuals who want it as shortly as doable.”

Knowledge from the CLL14 examine shall be submitted to world well being authorities. Venclexta together with Rituxan® (rituximab) has been permitted by the U.S. Meals and Drug Administration (FDA) for the remedy of individuals with CLL or small lymphocytic lymphoma, with or with out 17p deletion, who’ve obtained at the very least one prior remedy. A supplemental New Drug Software (sNDA) is at the moment underneath assessment by the FDA for Venclexta together with a hypomethylating agent or together with low dose cytarabine for the remedy of individuals with beforehand untreated acute myeloid leukemia (AML) who’re ineligible for intensive chemotherapy, with a call anticipated by finish of 12 months.

A strong medical growth program for Venclexta is ongoing in a number of kinds of blood most cancers, together with AML and a number of myeloma. Gazyva continues to be investigated together with permitted and investigational molecules in CLL and follicular lymphoma.

Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group. It’s collectively commercialized by the businesses in the USA and commercialized by AbbVie outdoors of the USA.

Supply:

https://www.gene.com/

Posted in: Drug Trial Information | Medical Situation Information

Tags: Acute Myeloid Leukemia, Anaphylaxis, Antibody, Apoptosis, Child, Biogen, Biotechnology, Delivery Management, Bleeding, Blood, Blood Most cancers, Mind, Breast Milk, Breastfeeding, Calcium, Most cancers, Cell, Cell Dying, Chemotherapy, Chest Ache, Kids, Power Lymphocytic Leukemia, Constipation, Cough, Dialysis, Diarrhea, Physician, Fatigue, Fertility, Fever, Follicular Lymphoma, Gene, Gout, Grapefruit, HBV, Headache, Healthcare, Coronary heart, Hematology, Hepatitis B, Hepatitis B Virus, Hodgkin’s Lymphoma, Immune System, Immunization, Joint Ache, Kidney, Kidney Failure, Leukemia, Liver, Liver Illness, Lymphoma, Medication, Molecule, Monoclonal Antibody, A number of Myeloma, Muscle, Myeloid Leukemia, Myeloma, Nausea, Neutropenia, New Drug Software, Non-Hodgkin’s Lymphoma, Ache, Pharmacist, Platelets, Potassium, Being pregnant, Programmed Cell Dying, Protein, Analysis, Respiratory, Rituximab, Sinusitis, Pores and skin, Dietary supplements, Thrombocytopenia, Tiredness, Tumor, Tumor Lysis Syndrome, Uric Acid, Urinary Tract An infection, Vaccine, Virus, Vomiting, Strolling, White Blood Cell

Section 1 medical trial inspecting topical cream plus influenza vaccine is underway

 

A Section 1 medical trial inspecting whether or not a topical cream can improve the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor School of Medication in Houston. Investigators are evaluating whether or not imiquimod cream, which is usually used to deal with genital warts and sure pores and skin cancers, can enhance the physique’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 wholesome adults ages 18-50 years. Baylor is likely one of the Vaccine and Remedy Analysis Items (VTEUs)–a community of medical analysis websites that may quickly enroll massive volunteer cohorts to guage experimental vaccines in opposition to infectious illnesses. The VTEUs are funded and managed by the Nationwide Institute of Allergy and Infectious Illnesses (NIAID), a part of the Nationwide Institutes of Well being.

H5N1 is an avian influenza virus that causes extreme respiratory sickness in birds. In uncommon circumstances, people have contracted H5N1 influenza by way of direct or oblique contact with contaminated birds, reminiscent of poultry. Infections in folks will be severe and deadly–the World Well being Group reported 860 instances of H5N1 influenza, 454 of them deadly, from 2003 by way of July 20, 2018. H5N1 influenza at the moment doesn’t unfold simply from human to human. Nonetheless, like all influenza viruses, the virus undergoes fixed genetic modifications, and it’s attainable that it might grow to be extra simply transmissible and trigger a pandemic.

Members within the VTEU trial will obtain an H5N1 vaccine (manufactured by Sanofi Pasteur, primarily based in Swiftwater, Pennsylvania) that was designed to be used in a possible pandemic. The vaccine, developed with some NIAID help, is created from an inactivated, or “killed,” influenza virus. After the vaccine was accredited by the Meals and Drug Administration (FDA) in 2007, it was added to the Nationwide Pre-pandemic Influenza Vaccine Stockpile.

“NIAID is happy to help a medical trial evaluating an modern approach to enhance immune responses to a pre-pandemic vaccine,” mentioned NIAID Director Anthony S. Fauci, M.D. “The Vaccine and Remedy Analysis Items stay a vital part of our pandemic influenza preparedness efforts.”

Imiquimod cream prompts the innate immune system–the physique’s fast protection in opposition to invading pathogens. Investigators in Hong Kong lately carried out two medical trials of imiquimod cream and seasonal inactivated influenza vaccine. One medical trial enrolled aged members, and the opposite enrolled younger adults. The imiquimod cream was usually well-tolerated, and aged and younger members who utilized the cream earlier than vaccination generated considerably extra strong immune responses than these in management teams who didn’t obtain imiquimod.

The immune-boosting properties of imiquimod might stretch the provision of H5N1 vaccines as a result of fewer doses can be required to attain ample immunity in recipients. This is able to permit extra folks to be vaccinated in an outbreak.

Hana M. El Sahly, M.D., affiliate professor, Division of Molecular Virology and Microbiology at Baylor School of Medication, serves because the principal investigator for the medical trial. All trial members will obtain two intradermal doses of the H5N1 vaccine, 21 days aside. Intradermal supply with a needle and syringe requires a exact strategy of inserting the needle within the pores and skin at a sure angle. To scale back variability, examine clinicians are utilizing a microneedle injector, the MicronJet600 (manufactured by NanoPass, primarily based in Ness Ziona, Israel), to ship the vaccine.

Members will probably be randomly assigned to one in all two remedy teams. One group may have Aldara (FDA-approved imiquimod cream manufactured by Valeant Pharmaceutical Worldwide, Inc., primarily based in Laval, Canada) utilized to their higher arm earlier than every vaccination. The cream, which is provided in single-use packets, is rubbed in in order that it’s absolutely absorbed. After ready roughly 5 to 15 minutes, clinicians will then administer the vaccine to the higher arm the place the cream was utilized. The identical course of will probably be adopted within the management group; nevertheless, as an alternative of receiving imiquimod cream, management group members may have a placebo aqueous cream utilized in the identical style earlier than each vaccinations. The trial is double-blind, which means the members and the investigators have no idea who obtained every kind of topical cream. Research clinicians will monitor members for any injection web site reactions reminiscent of redness and swelling, or different reactions reminiscent of fever, headache or nausea. After every injection, members should chorus from washing their arm for 4 to 6 hours.

Members will return to the clinic at common intervals over the course of seven months to have blood drawn in order that investigators can check samples for an immune response. After every vaccination, members will take residence a diary card to document any signs and drugs taken at residence. An unbiased information and security monitoring committee will assessment members’ medical and security information at specified time factors and in any other case as wanted.

The primary medical trial participant was vaccinated on June 19, 2018, and investigators anticipate to have early examine outcomes by the top of the yr. For extra info, go to ClinicalTrials.gov and search identifier NCT03472976.

Supply:

https://www.niaid.nih.gov/news-events/clinical-trial-testing-topical-cream-plus-influenza-vaccine-progress